US$ 22.75
glucagon like peptide 1 glp 1 agonists PDB-101: Molecule of the Month: GLP-1 Receptor Mechanisms of Action and Therapeutic
Description
With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

The primary outcome was change in HbA1c from baseline

225 mg of Hericium erinaceus extract (equivalent to 1.8 g of dried mushroom), titrated to 30% polysaccharides

They act by binding to GLP-1 receptors, ...

Recently, multiple case reports and studies indicating safety risks for these medications and their use in patients planning to undergo general anesthesia have been published, as retained gastric contents can lead to intraoperative aspiration

What is it and what are the pros and cons?
